Evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa - German IPEP trial

Study identifier:Zx-002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Quality assurance project in patients with advanced prostate carcinoma - evaluation of tolerability, quality of life and usage of Zoladex 10,8 SafeSystem

Medical condition

Prostate Carcinoma

Phase

Healthy volunteers

Study drug

Sex

Male

Actual Enrollment

1950

Study type

Observational

Age

N/A

Date

Study Start Date: 01 Jun 2005

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1142&filename=CSR-Zx-002.pdf
Download
CSR-Zx-002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca GmbH Clinical Study

+49 (0) 800 22 88 66 0

info@astrazeneca.de

Investigators

Principal Investigator

H Brasch

AstraZeneca